PepGen Inc. DM1 Trial Shows Promising Results, But Financial Challenges Loom

PepGen Inc. (PEPG) has reported positive data from its DM1 treatment trial, advancing to phase 2, which has been well-received by the market. However, the company recently discontinued its Duchenne Muscular Dystrophy (DMD) trials. With limited cash reserves and significant future R&D expenses, the company faces potential equity raises and financial risks, raising questions about its long-term viability and upside potential for investors.